Theradaptive Begins Clinical Trials to Pave Way for Dental Bone Regeneration Using OsteoAdapt DE
Theradaptive, Inc., a pioneering biotechnology company focused on targeted protein therapeutics for tissue regeneration, made headlines with its recent announcement regarding the RESTORE International Phase I/II Feasibility Study. This study marks an important milestone as it sees the first patient treated using OsteoAdapt™ DE, a cutting-edge regenerative product designed specifically for enhancing bone growth during alveolar ridge augmentation, a critical dental reconstruction procedure.
The initiative is spearheaded by Dr. Gal Avishai at Rabin Medical Center located in Petach Tikva, Israel. Dr. Avishai expressed the pressing need for enhanced treatment solutions in both dental and craniomaxillofacial repair. OsteoAdapt DE, as he noted, holds the promise of delivering significant and consistent bone regeneration, which could fundamentally elevate patient care standards. This technology is expected to be of great importance, particularly in jaw restoration after traumatic fractures or oncological resections.
Alveolar ridge augmentation plays a vital role in dental procedures, particularly when preserving bone lost due to tooth extractions, disease, or trauma. It serves as a fundamental step to ensure sufficient bone volume for successfully placing dental implants. Dental professionals commonly use various materials such as xenografts, allografts, or synthetic substitutes, which mainly rely on passive osteoconduction to support new bone development. While these materials are prevalent, they often integrate slowly and can leave notable residual graft material that raises the likelihood of complications during the implant placement.
OsteoAdapt DE differentiates itself from conventional grafts by incorporating an osteoinductive component that actively stimulates and facilitates bone formation while minimizing leftover material at the time of implant placement. This innovative product employs AMP2™, which is Theradaptive’s proprietary and engineered form of recombinant human bone morphogenetic protein-2 (BMP-2). This unique approach enables targeted recruitment of stem cells and facilitates controlled bone regeneration, aiming to shorten healing times and enhance surgical outcomes—positioning patients for quicker implant readiness. As a significant element of the RESTORE trial, the efficacy and safety of OsteoAdapt DE will be compared against a standard xenograft bone graft.
This groundbreaking study is further endorsed by the Armed Forces Institute of Regenerative Medicine (AFIRM), having secured a Fiscal Year 2024 Clinical Trial Award. This collaboration, facilitated via the Wake Forest Institute for Regenerative Medicine (WFIRM) and funded by the Defense Health Agency Research and Engineering Directorate, focuses on advancing regenerative medicine technologies to treat traumatic injuries encountered on the battlefield—specifically, those affecting the face and jaw. The potential therapeutic impact of OsteoAdapt DE in these critical areas cannot be overstated.
According to Luis Alvarez, PhD, CEO and Founder of Theradaptive, achieving precise bone regeneration remains a significant challenge in clinical practice. With the backing from AFIRM, the progress of this study symbolizes a substantial advancement in the technology that they have developed. Alvarez emphasizes that this effort aims to deliver solutions that benefit a wide array of patients, whether recovering from traumatic injuries or receiving advanced dental care, especially in locations that demand rapid responses.
The RESTORE trial is Theradaptive's second clinical endeavor, following the OASIS trial, which is nearing completion. The latter study examines OsteoAdapt SP for lumbar spinal fusion indications under an FDA-approved Investigational Device Exemption (IDE). Together, these trials underscore the vast potential of the OsteoAdapt platform across different therapeutic landscapes, highlighting its effectiveness in facilitating targeted and reliable bone regeneration.
In summary, Theradaptive is at the forefront of innovative treatments aimed at regenerative medicine. By focusing on products like OsteoAdapt DE, the company is not only advancing dental care but is also paving the way for enhanced treatment options that may significantly improve the recovery process for patients suffering from bone loss due to various medical conditions and injuries. As the trials progress, the implications for regenerative medicine in both civilian and military contexts will be closely monitored, with the hope that such technologies can reshape the future of health care.
For more details about Theradaptive and its clinical efforts, visit their official website or follow their social media for the latest updates.
The initiative is spearheaded by Dr. Gal Avishai at Rabin Medical Center located in Petach Tikva, Israel. Dr. Avishai expressed the pressing need for enhanced treatment solutions in both dental and craniomaxillofacial repair. OsteoAdapt DE, as he noted, holds the promise of delivering significant and consistent bone regeneration, which could fundamentally elevate patient care standards. This technology is expected to be of great importance, particularly in jaw restoration after traumatic fractures or oncological resections.
Understanding Alveolar Ridge Augmentation
Alveolar ridge augmentation plays a vital role in dental procedures, particularly when preserving bone lost due to tooth extractions, disease, or trauma. It serves as a fundamental step to ensure sufficient bone volume for successfully placing dental implants. Dental professionals commonly use various materials such as xenografts, allografts, or synthetic substitutes, which mainly rely on passive osteoconduction to support new bone development. While these materials are prevalent, they often integrate slowly and can leave notable residual graft material that raises the likelihood of complications during the implant placement.
The Innovation of OsteoAdapt DE
OsteoAdapt DE differentiates itself from conventional grafts by incorporating an osteoinductive component that actively stimulates and facilitates bone formation while minimizing leftover material at the time of implant placement. This innovative product employs AMP2™, which is Theradaptive’s proprietary and engineered form of recombinant human bone morphogenetic protein-2 (BMP-2). This unique approach enables targeted recruitment of stem cells and facilitates controlled bone regeneration, aiming to shorten healing times and enhance surgical outcomes—positioning patients for quicker implant readiness. As a significant element of the RESTORE trial, the efficacy and safety of OsteoAdapt DE will be compared against a standard xenograft bone graft.
Military Relevance and Support
This groundbreaking study is further endorsed by the Armed Forces Institute of Regenerative Medicine (AFIRM), having secured a Fiscal Year 2024 Clinical Trial Award. This collaboration, facilitated via the Wake Forest Institute for Regenerative Medicine (WFIRM) and funded by the Defense Health Agency Research and Engineering Directorate, focuses on advancing regenerative medicine technologies to treat traumatic injuries encountered on the battlefield—specifically, those affecting the face and jaw. The potential therapeutic impact of OsteoAdapt DE in these critical areas cannot be overstated.
According to Luis Alvarez, PhD, CEO and Founder of Theradaptive, achieving precise bone regeneration remains a significant challenge in clinical practice. With the backing from AFIRM, the progress of this study symbolizes a substantial advancement in the technology that they have developed. Alvarez emphasizes that this effort aims to deliver solutions that benefit a wide array of patients, whether recovering from traumatic injuries or receiving advanced dental care, especially in locations that demand rapid responses.
Theradaptive's Broader Vision
The RESTORE trial is Theradaptive's second clinical endeavor, following the OASIS trial, which is nearing completion. The latter study examines OsteoAdapt SP for lumbar spinal fusion indications under an FDA-approved Investigational Device Exemption (IDE). Together, these trials underscore the vast potential of the OsteoAdapt platform across different therapeutic landscapes, highlighting its effectiveness in facilitating targeted and reliable bone regeneration.
In summary, Theradaptive is at the forefront of innovative treatments aimed at regenerative medicine. By focusing on products like OsteoAdapt DE, the company is not only advancing dental care but is also paving the way for enhanced treatment options that may significantly improve the recovery process for patients suffering from bone loss due to various medical conditions and injuries. As the trials progress, the implications for regenerative medicine in both civilian and military contexts will be closely monitored, with the hope that such technologies can reshape the future of health care.
For more details about Theradaptive and its clinical efforts, visit their official website or follow their social media for the latest updates.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.